Unleashing the potential of mTOR inhibition through precision medicine and a proven albumin-based platform
At Aadi Bioscience, our mission is to dramatically improve the lives of people with mTOR-driven diseases. We believe success depends on leveraging the latest genomic profiling technology and predictive biomarkers to identify the patients most likely to benefit from mTOR inhibition, then treating those patients with the best mTOR inhibitor.
- Identify diseases with mTOR pathway driver mutations and strong evidence of mTOR involvement in pathology of disease
- Target genomically defined subgroups across cancer types with mTOR pathway aberrations including TSC1, TSC2, and PTEN who are most likely to respond to mTOR treatment
- Treat patients with nab-sirolimus (ABI-009), a potential best-in-class mTOR inhibitor leveraging the proven albumin-bound platform